J&J COVID-19 vaccine trial moves into late stage

Latest News

J&J COVID-19 vaccine trial moves into late stage

Wednesday, September 23, 2020

Print this page Email A Friend!


WASHINGTON,United States(AFP) — Johnson & Johnson said Wednesday it was entering the final Phase 3 stage of its COVID-19 vaccine clinical trial following positive results in earlier stages.

The trial will seek to enrol up to 60,000 volunteers across more than 200 sites in the US and around the world, the company and the US National Institutes for Health (NIH), which is providing funding, said.

With the move, J&J becomes the tenth maker globally to conduct a Phase 3 trial against COVID-19, and the fourth in the US.

The company, which is developing the vaccine on a not-for-profit basis through its subsidiary Janssen, said it anticipated the drug would be ready for emergency approval by early 2021 if proven safe and effective.

"As COVID-19 continues to impact the daily lives of people around the world, our goal remains the same — leveraging the global reach and scientific innovation of our company to help bring an end to this pandemic," said Alex Gorsky, the company's chairman and CEO.

Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Diseases, added: "Four COVID-19 vaccine candidates are in Phase 3 clinical testing in the United States just over eight months after SARS-CoV-2 was identified."

"This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated, strategic approach across government, industry and academia."

The US has given J&J about US$1.45 billion in funding under Operation Warp Speed.

The vaccine is based on a single dose ofa cold-causing adenovirus, modified so that it can no longer replicate, combined with a part of the new coronavirus called the spike protein that it uses to invade human cells.

J&J used the same technology in its Ebola vaccine which received marketing approval from the European Commission in July.

The company said it was poised to imminently publish the results from an earlier stage of the trial on a medical preprint site.

Pre-clinical testing on rhesus macaque monkeys that were published in the journal Nature showed it provided complete or near-complete protection against virus infection in the lungs and nose.

Like several other Phase 3 trials that are underway, its primary objective is to test whether the vaccine can prevent symptomatic COVID-19.


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login


ADVERTISEMENT




POST A COMMENT

HOUSE RULES

1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.

6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.

7. Lastly, read our Terms and Conditions and Privacy Policy



comments powered by Disqus
ADVERTISEMENT

Poll

ADVERTISEMENT
ADVERTISEMENT

Today's Cartoon

Click image to view full size editorial cartoon
ADVERTISEMENT